Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 9099–9110 | Cite as

RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines

  • Masanobu Tsubaki
  • Tomoya Takeda
  • Misako Yoshizumi
  • Emi Ueda
  • Tatsuki Itoh
  • Motohiro Imano
  • Takao Satou
  • Shozo Nishida
Original Article

Abstract

Interaction between multiple myeloma (MM) cells and the bone marrow microenvironment plays a critical role in MM pathogenesis and the development of drug resistance. Recently, it has been reported that MM cells express the receptor activator of nuclear factor-κB (NF-κB) (RANK). However, the role of the RANK/RANK ligand (RANKL) system in drug resistance remains unclear. In this study, we demonstrated a novel function of the RANK/RANKL system in promoting drug resistance in MM. We found that RANKL treatment induced drug resistance in RANK-expressing but not RANK-negative cell lines. RANKL stimulation of RANK-expressing cells increased multidrug resistance protein 1 (MDR1), breast cancer resistance protein (BCRP), and lung resistance protein 1 (LRP1) expression and decreased Bim expression through various signaling molecules. RNA silencing of Bim expression induced drug resistance, but the RANKL-mediated drug resistance could not be overcome through the RNA silencing of MDR1, BCRP, and LRP1 expression. These results indicate that the RANK/RANKL system induces chemoresistance through the activation of multiple signal transduction pathways and by decreasing Bim expression in RANK-positive MM cells. These findings may prove to be useful in the development of cell adhesion-mediated drug resistance inhibitors in RANK-positive MM cells.

Keywords

Multiple myeloma RANK RANKL CAM-DR Bim 

Notes

Acknowledgments

This work was supported in part by a grant-in-aid for Scientific Research (C) (grant number 15K08116), grant-in-aid for Young Scientists (B) (grant number 25860071) from the Japan Society for the Promotion of Science (JSPS), and by Ministry of Education, Culture, Sports, Science, and Technology (MEXT)-Supported Program for the Strategic Reseach Foundation at Private Universities, 2014-2018 (grant number S1411037).

Compliance with ethical standards

Conflicts of interest

None

Supplementary material

13277_2015_4761_MOESM1_ESM.pdf (430 kb)
ESM 1 (PDF 429 kb)

References

  1. 1.
    Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585–98. doi: 10.1038/nrc2189.CrossRefPubMedGoogle Scholar
  2. 2.
    Tsubaki M, Satou T, Itoh T, Imano M, Komai M, Nishinobo M, et al. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leuk Res. 2012;36(10):1315–22. doi: 10.1016/j.leukres.2012.07.003.CrossRefPubMedGoogle Scholar
  3. 3.
    Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001;20(1-2):43–50. doi: 10.1023/A:1013156407224.CrossRefPubMedGoogle Scholar
  4. 4.
    Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003;63(22):7900–6.PubMedGoogle Scholar
  5. 5.
    Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14(9):2519–26. doi: 10.1158/1078-0432.CCR-07-2223.CrossRefPubMedGoogle Scholar
  6. 6.
    Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000;38(1-2):71–81. doi: 10.3109/10428190009060320.PubMedGoogle Scholar
  7. 7.
    Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009;69(3):1009–15. doi: 10.1158/0008-5472.CAN-08-2419.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev. 2009;109(7):2989–3011.CrossRefPubMedGoogle Scholar
  9. 9.
    Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene. 2003;22(47):7458–67.CrossRefPubMedGoogle Scholar
  10. 10.
    Tsubaki M, Takeda T, Ogawa N, Sakamoto K, Shimaoka H, Fujita A, et al. Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells. Leuk Res. 2015;39(4):445–52. doi: 10.1016/j.leukres.2015.01.016.CrossRefPubMedGoogle Scholar
  11. 11.
    Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, et al. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. Leuk Res. 2014;38(1):121–30. doi: 10.1016/j.leukres.2013.CrossRefPubMedGoogle Scholar
  12. 12.
    Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, et al. Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs. Eur J Cancer. 2013;49(17):3708–17. doi: 10.1016/j.ejca.2013.07.010.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, et al. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 2014;124(17):2687–97. doi: 10.1182/blood-2014-03-564534.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Murray ME, Gavile CM, Nair JR, Koorella C, Carlson LM, Buac D, et al. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood. 2014;123(24):3770–9. doi: 10.1182/blood-2013-10-530964.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 2003;63(17):5438–45.PubMedGoogle Scholar
  16. 16.
    Sung B, Cho SG, Liu M, Aggarwal BB. Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling. Int J Cancer. 2011;129(9):2062–72. doi: 10.1002/ijc.25868.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–23. doi: 10.1038/16852.CrossRefPubMedGoogle Scholar
  18. 18.
    Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–42. doi: 10.1038/nature01658.CrossRefPubMedGoogle Scholar
  19. 19.
    Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, et al. Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation. J Biomed Sci. 2014;21:10. doi: 10.1186/1423-0127-21-10.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125(5):1780–9. doi: 10.1172/JCI76094.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Johnson KA, Brown PH. Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol. 2010;37(4):345–58. doi: 10.1053/j.seminoncol.2010.05.012.CrossRefPubMedGoogle Scholar
  22. 22.
    Sui H, Fan ZZ, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012;40(2):426–35. doi: 10.1177/147323001204000204.CrossRefPubMedGoogle Scholar
  23. 23.
    Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006;108(2):645–52. doi: 10.1182/blood-2005-11-4639.CrossRefPubMedGoogle Scholar
  24. 24.
    Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia. 2005;7(7):646–57.Google Scholar
  25. 25.
    Lai FP, Cole-Sinclair M, Cheng WJ, Quinn JM, Gillespie MT, Sentry JW, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol. 2004;126(2):192–201. doi: 10.1111/j.1365-2141.2004.05018.x.CrossRefPubMedGoogle Scholar
  26. 26.
    Calvani N, Cafforio P, Silvestris F, Dammacco F. Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol. 2005;130(6):926–38. doi: 10.1111/j.1365-2141.2005.05710.x.CrossRefPubMedGoogle Scholar
  27. 27.
    Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001;98(9):2784–90. doi: 10.1182/blood.V98.9.2784.CrossRefPubMedGoogle Scholar
  28. 28.
    Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med. 2006;203(8):1859–65. doi: 10.1084/jem.20052136.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103–7. doi: 10.1038/nature09495.CrossRefPubMedGoogle Scholar
  30. 30.
    Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, et al. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res. 2013;32:62. doi: 10.1186/1756-9966-32-62.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Cote GM. Rank ligand as a target in musculoskeletal neoplasms. Curr Rev Musculoskelet Med. 2015;8:339–43. doi: 10.1007/s12178-015-9310-y.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Beristain AG, Narala SR, Di Grappa MA, Khokha R. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci. 2012;125:943–55. doi: 10.1242/jcs.094029.CrossRefPubMedGoogle Scholar
  33. 33.
    Gonzalez-Suarez E, Branstetter D, Armstrong A, Dinh H, Blumberg H, Dougall WC. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol. 2007;27:1442–54. doi: 10.1128/MCB.01298-06.CrossRefPubMedGoogle Scholar
  34. 34.
    Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life. 2005;57(6):389–95. doi: 10.1080/15216540500137669.CrossRefPubMedGoogle Scholar
  35. 35.
    Blair HC, Robinson LJ, Zaidi M. Osteoclast signalling pathways. Biochem Biophys Res Commun. 2005;328(3):728–38. doi: 10.1016/j.bbrc.2004.11.077.CrossRefPubMedGoogle Scholar
  36. 36.
    Galski H, Sivan H, Lazarovici P, Nagler A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies. Leuk Res. 2006;30(9):1151–8. doi: 10.1016/j.leukres.2006.02.016.CrossRefPubMedGoogle Scholar
  37. 37.
    Leung KT, Li KK, Sun SS, Chan PK, Ooi VE, Chiu LC. Activation of the JNK pathway promotes phosphorylation and degradation of BimEL—a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis. 2008;29(3):544–51. doi: 10.1093/carcin/bgm294.CrossRefPubMedGoogle Scholar
  38. 38.
    De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010;115(12):2430–40. doi: 10.1182/blood-2009-07-232801.CrossRefPubMedGoogle Scholar
  39. 39.
    Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood. 2007;109(12):5430–8. doi: 10.1182/blood-2006-10-047951.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Masanobu Tsubaki
    • 1
  • Tomoya Takeda
    • 1
  • Misako Yoshizumi
    • 1
  • Emi Ueda
    • 1
  • Tatsuki Itoh
    • 2
  • Motohiro Imano
    • 3
  • Takao Satou
    • 4
  • Shozo Nishida
    • 1
  1. 1.Division of PharmacotherapyKinki University School of PharmacyKowakaeJapan
  2. 2.Department of Food Science and NutritionKinki University School of AgricultureNaraJapan
  3. 3.Department of SurgeryKinki University School of MedicineOsakasayamaJapan
  4. 4.Department of PathologyKinki University School of MedicineOsakasayamaJapan

Personalised recommendations